Uttamkumar Vijaykumar Shinde

Uttamkumar Vijaykumar Shinde

Director Director DIN 08896445
DIN 08896445 First appointment Sep 2020 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Sep 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Uttamkumar Vijaykumar Shinde

Data last updated:

Uttamkumar Vijaykumar Shinde was a Director at Impact Therapeutics Limited (2020–2022). The company operates in Pharma.

DIN 08896445
Primary Designation Director
Industry Pharma
First Appointment 28 Sep 2020

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Impact Therapeutics Limited U51909MH2010PLC211564
Director28 Sep 20202010₹1,499 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Impact Therapeutics Limited
Premium access

Shareholding and investment profile for Uttamkumar Vijaykumar Shinde

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Uttamkumar Vijaykumar Shinde

Uttamkumar Vijaykumar Shinde was first appointed on 28 Sep 2020 as Director at Impact Therapeutics Limited.

Uttamkumar Vijaykumar Shinde held 1 earlier board appointment: Impact Therapeutics Limited (Director, 28 Sep 2020 to 06 May 2022).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available